First quarter total revenue of approximately EUR 5.9 million ( USD 7.8 million ), up 23% year-over-year Ten lithotripsy devices sold in first quarter 2013 Received FDA acceptance for PMA filing on March 26, 2013 , for Ablatherm®-HIFU for treatment of low risk, localized prostate cancer LYON, France

EDAP Announces Ablatherm Fusion World Premiere during American Urology Association Annual Meeting in Boston, MA , May 12-16, 2017 EDAP to Showcase Ablatherm Fusion and Sonolith i-move at AUA Booth #130 LYON, France , May 11, 2017 -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic

Multicenter study to commence in September in France Reinforces company’s recent shift in strategic focus toward development of additional high-value HIFU tissue ablation indications LYON, France , August 25, 2020 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic

  Study to begin enrolling patients in Q2 2023   Endometriosis represents significant expansion opportunity for Focal One  LYON, France, November 30, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic therapeutic ultrasound, today announced that the Company has

Supported by Expanding Physician Utilization of HIFU in Europe

Marc Oczachowski to Assume CEO Role Hugues de Bantel to Join Board with Focus on French and US Programs

Billing code will take effect July 1st, 2017 LYON, France , May 22, 2017 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, announced today that the Centers for Medicare and Medicaid Services (CMS) have established a new billing code for HIFU ablation of

60 Patients Completed Enrollment in Under 9 Months Study Results Expected in the Second Half of 2024 LYON, France, February 1, 2024 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that it has completed enrollment in its Phase 3 study (Endo-HIFU-R2)

EDAP Announces Details on Termination Agreement With HealthTronics LYON, France, April 12 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (NASDAQ: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development, production,

Deadline for Appeals Passes With no Notice of Appeal Filed